All samples were immediately transferred to the laboratory in ice bath for quantitative measurement of neutrophil CD64
expression as previously described (10, 15).
Cells display CD33 (l00%), CD117 (93%) CD13 (64%), CD64
(99%), CD38 (90%), and myeloperoxidase (81%), HLA-DR (19%).
14) Multiple blast populations characterize inv(16) immature blasts with high CD34 and CD117 expression and populations differentiating toward mono cytic (CD14, CD4, CD11b, CD11c, CD64
positive) and granulocytic (CD13, CD33, CD15, myeloperoxidase positive) lineages.
The panel of antibodies (with associated function) we used was CD23 [low-affinity immunoglobulin (Ig) E receptor], Fee receptor-1 (FceRl; high-affinity IgE receptor), CD80, CD86, CD40, HIA-DR (a major histocompatibility complex class II; antigen presentation), CDla (antigen presentation), CD1 lb/CR3, CD54/intercellular adhesion molecule-1 (1CAM-1; complement-mediated phagocytosis, cell migration; immune complex binding), CD14, CD16, and CD64
(lipopoly-saccharide; inflammation; innate immunity).
binding domain that binds to the high affinity CD64
Bakteriyel enfeksiyonlar sirasinda aktive lokositlerde CD11 b, CD64
ve CD69 gibi yuzey antijenlerinin ekspresyonu artar (22, 25).
cells lacking markers CD2, DC3, CD10, CD16, CD18, CD31, CD64
and CD140b), isolated from one primary breast cancer and eight malignant pleural effusion samples, were able to form heterogeneous tumours containing both the CD[44.
In addition, CD14 and CD64
stained negative which is also suggestive of AMKL.
However, the mechanism of action is unknown, since most [gamma][delta] T cells lack the Fc receptors CD16, CD32, and CD64
The following FITC-labeled receptors were used: CD64
for Fc-[gamma]RI, CD32 for Fc-[gamma]RII, and CD16 for Fc-[gamma]RIII.
Scancell's ImmunoBody(R) technology uses human antibodies as vectors to target clinically relevant T-cell epitopes to activated dendritic cells via the high affinity CD64
receptor thereby initiating cellular immunity against cancers or chronic infectious diseases.
Also, because CRP appears to mediate its effects in HAECs via CD32 and CD64
, we pretreated HAECs with blocking antibodies to CD16, CD32, and CD64
before treatment with CRP.